Literature DB >> 12456916

Continuous propofol infusion in 142 critically ill children.

David N Cornfield1, Ken Tegtmeyer, Michael D Nelson, Carlos E Milla, Michael Sweeney.   

Abstract

OBJECTIVE: In recent years, continuous intravenous propofol infusion has been widely used in pediatric intensive care units. Several case reports have raised concerns about its safety. The objective of this study was to report our experience with continuous intravenous propofol in consecutive patients during an 18-month period.
METHODS: The study design was a retrospective review of a case series. Case was defined as a critically ill child who was treated with continuous intravenous propofol. The attending physician staff agreed to prescribe propofol via continuous intravenous infusion at a dose not to exceed 50 microg/kg/min. The protocol allowed for each patient to receive an additional intravenous bolus of propofol at a dose of 1 mg/kg no more than once per hour. The study entailed data collection from consecutive patients who were prescribed a continuous infusion of propofol in either the pediatric intensive care unit or bone marrow transplant unit.
RESULTS: Data from 142 patients were analyzed. Each patient enrolled was adequately sedated. Administration of propofol via continuous intravenous infusion was not associated with metabolic acidosis or hemodynamic compromise. No patient in the study group was inadvertently extubated or had a central venous catheter accidentally discontinued.
CONCLUSIONS: Propofol can be safely and effectively used to provide sedation to critically ill infants and children. We speculate that continuous infusion of propofol for extended periods of time should not exceed 67 microg/kg/min.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456916     DOI: 10.1542/peds.110.6.1177

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

Review 1.  Propofol: a review of its role in pediatric anesthesia and sedation.

Authors:  Vidya Chidambaran; Andrew Costandi; Ajay D'Mello
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

3.  Myotoxicity Induced by Antiepileptic Drugs: Could be a Rare but Serious Adverse Event?

Authors:  Antonio Siniscalchi; Scott Mintzer; Giovambattista De Sarro; Luca Gallelli
Journal:  Psychopharmacol Bull       Date:  2021-11-03

4.  Treatment of status epilepticus: an international survey of experts.

Authors:  James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

Review 5.  Survey of Pharmacists Regarding the Use of Propofol Infusions in the PICUs in North America.

Authors:  Kenneth J Kurek; Aaron A Harthan; Sandeep Tripathi
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

6.  Propofol-based palliative sedation in terminally ill children with solid tumors: A case series.

Authors:  Evelina Miele; Mastronuzzi Angela; M Giuseppina Cefalo; Francesca Del Bufalo; M Debora De Pasquale; Serra Annalisa; Gian Paolo Spinelli; De Sio Luigi
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.889

7.  Propofol in the Pediatric Intensive Care Unit, a Safe and Effective Agent in Reducing Pain and Sedation Infusions: A Single-Center Retrospective Study.

Authors:  Sruti Uppuluri; Enrique G Villarreal; Vincent Dorsey; Faeeq Yousaf; Juan S Farias; Saul Flores; Rohit S Loomba
Journal:  Cureus       Date:  2022-08-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.